NYSE: GENIGenius Sports Ltd Stock
$10.83-0.40 (-3.56%)
Updated Dec 5, 2025
GENI Price
$10.83
Fair Value Price
N/A
Market Cap
$2.74B
52 Week Low
$8.15
52 Week High
$13.73
P/E
-23.04x
P/B
3.8x
P/S
5.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$604.52M
Earnings
-$119.17M
Gross Margin
22%
Operating Margin
-20.37%
Profit Margin
-19.7%
Debt to Equity
0.45
Operating Cash Flow
$84M
Beta
1.68
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GENI Overview
dMY Technology Group, Inc. II intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Las Vegas, Nevada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GENI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Internet Content & Information
Industry Rating
C
GENI
Ranked#45 of 52
Ranked#45 of 52
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.07 | A | |
| $15.43 | A | |
| $3.95 | A |
Be the first to know about important GENI news, forecast changes, insider trades & much more!
GENI News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GENI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GENI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GENI is good value based on its book value relative to its share price (3.8x), compared to the US Internet Content & Information industry average (8.5x)
P/B vs Industry Valuation
GENI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GENI due diligence checks available for Premium users.
Valuation
GENI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-23.04x
Industry
31.89x
Market
46.7x
GENI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.8x
Industry
8.5x
GENI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GENI's financial health
Profit margin
Revenue
$166.3M
Net Income
-$28.8M
Profit Margin
-17.3%
GENI's Earnings (EBIT) of -$123.15M... subscribe to Premium to read more.
Interest Coverage Financials
GENI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.0B
Liabilities
$326.6M
Debt to equity
0.45
GENI's short-term assets ($466.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GENI's short-term assets ($466.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GENI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GENI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$27.2M
Investing
-$38.7M
Financing
-$6.0k
GENI's operating cash flow ($84.08M)... subscribe to Premium to read more.
Debt Coverage Financials
GENI vs Internet Content & Information Stocks
Genius Sports Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.